Drug-Related Lipid Metabolism Abnormalities: A Real-World Pharmacovigilance Exploratory Analysis Based on U.S. FDA Adverse Event Reporting System (FAERS)
January 2026
in “
Nutrición Hospitalaria
”
Studysummary In this study, researchers identified significant signals indicating previously unrecognized risks of lipid metabolism abnormalities for several drugs, urging the need for better monitoring and label updates.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
This study investigates drug-induced lipid metabolism disorders (DILMD) using the U.S. FDA's Adverse Event Reporting System (FAERS) database, analyzing 140,110 reports of related adverse events. Significant associations were found for drugs like risperidone, adalimumab, and rofecoxib, with 29 out of the top 50 drugs lacking explicit lipid metabolism risk warnings in their labels. Novel risk signals were identified for Carthamus Tinctorius, Rofecoxib, Alendronic Acid, Finasteride, and Eicosapentaenoic Acid5. The study highlights older adults and individuals with higher body weight as particularly vulnerable, emphasizing the need for improved monitoring and timely updates to drug labels to address these emerging risks.
